Pharmaceuticals, Biotechnology and Life Sciences
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating…
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of…
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of…
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal…
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company…
Wa’el Hashad Wa’el Hashad, CEO, Longeveron Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as…
Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…
• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with…
PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company…
– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – –…